Secobarbital is a short-acting barbiturate that depresses the central nervous system through GABA-A receptor potentiation.
Once widely prescribed for insomnia and anesthesia premedication but now rarely prescribed due to its narrow therapeutic index, high addiction potential, and near-complete displacement by benzodiazepines and non-benzodiazepine sedatives.
Today, secobarbital is most commonly encountered in the context of medical aid in dying (under the brand name Seconal), substance misuse, and toxicology cases where its interaction with other CNS depressants creates rapidly lethal overdose scenarios. Understanding what secobarbital is matters because its risks have not diminished with its prescribing decline.
Key Takeaways
- Secobarbital is a Schedule II controlled substance under the DEA Controlled Substances Act, reflecting high abuse potential and accepted medical use with severe restrictions.
- Secobarbital’s therapeutic-to-lethal dose ratio is extremely narrow; a dose only 3 to 5 times the therapeutic range can produce fatal respiratory depression, making it one of the most dangerous sedative-hypnotics in clinical use.
- Barbiturate overdose deaths contributed significantly to the 1960s and 1970s prescription drug epidemic before regulatory restrictions, with secobarbital and pentobarbital among the most frequently implicated agents in fatal overdose cases according to FDA historical records.
- Sedative-hypnotic use disorder from barbiturates produces cross-tolerance with benzodiazepines and alcohol, and withdrawal can produce life-threatening seizures indistinguishable from alcohol withdrawal syndrome.
- Approximately 5.6 million Americans met DSM-5-TR criteria for sedative-hypnotic or anxiolytic use disorder in 2022, according to SAMHSA’s National Survey on Drug Use and Health.
What Is Secobarbital?
Secobarbital (sodium secobarbital, sold under the brand name Seconal) is a barbituric acid derivative classified as a short-acting barbiturate due to its rapid onset and 15 to 40-hour elimination half-life. It was first synthesized in 1928 by Eli Lilly and Company and entered widespread clinical use in the 1930s and 1940s as a sedative, hypnotic, and anesthesia premedication.
Secobarbital Drug Classification and Legal Status
Secobarbital is classified as a DEA Schedule II controlled substance, meaning it has a currently accepted medical use but carries high potential for abuse leading to severe psychological or physical dependence. The same schedule applies to methamphetamine, cocaine, and oxycodone, reflecting secobarbital’s significant abuse and overdose history.
- DEA classification: Schedule II (DEA code 2315)
- FDA status: Approved for short-term insomnia (7 to 10 days maximum) and pre-operative sedation; no long-term use indication
- Medical aid in dying use: Secobarbital 9-gram oral ingestion is the standard protocol under Oregon’s Death with Dignity Act and subsequent state laws, making it the primary current clinical application in the U.S.
How Secobarbital Differs from Benzodiazepines
Secobarbital and benzodiazepines both potentiate GABA-A receptor activity, but at different binding sites with critically different dose-response relationships that explain why barbiturates are far more lethal than benzodiazepines in overdose.
- GABA-A binding site: Benzodiazepines bind the benzodiazepine allosteric site on GABA-A receptors, increasing GABA’s effect but creating a ceiling beyond which further CNS depression cannot occur; barbiturates bind the barbiturate binding site on GABA-A, and at high doses can directly activate GABA-A receptors independent of GABA, bypassing this ceiling
- Therapeutic index: Benzodiazepines have a very wide therapeutic index (overdose deaths from benzodiazepines alone are rare without co-ingestion); secobarbital’s therapeutic index is 3 to 5, meaning the lethal dose is only 3 to 5 times the effective dose
- Clinical implication: This mechanistic difference explains why benzodiazepines largely replaced barbiturates for sedation and insomnia despite comparable efficacy, and why combined barbiturate-alcohol or barbiturate-opioid use is so rapidly lethal
How Secobarbital Works in the Brain
Secobarbital depresses the central nervous system through direct enhancement of GABA-A chloride ionophore activity, suppressing neuronal excitability across cortical, subcortical, and brainstem structures in a dose-dependent progression from sedation through respiratory failure.
GABA-A Receptor Mechanism
At therapeutic doses, secobarbital binds the GABA-A receptor complex at the barbiturate-binding domain, prolonging chloride channel opening duration in response to GABA, producing sedation and hypnosis. As plasma concentration rises toward toxic levels, secobarbital directly activates GABA-A receptors without GABA present, producing an increasingly non-reversible CNS depressant effect.
- Cortical suppression: GABA-A potentiation in the cerebral cortex reduces cortical excitability, producing sedation, impaired cognition, and at higher doses unconsciousness
- Reticular activating system depression: Secobarbital suppresses the ascending reticular activating system in the brainstem, which maintains wakefulness; at overdose concentrations this produces coma
- Medullary respiratory center suppression: High-dose secobarbital directly suppresses the medullary respiratory center’s chemoreceptor response to hypercapnia, causing respiratory arrest in overdose
CYP3A4 Metabolism and Drug Interactions
Secobarbital induces cytochrome P450 enzyme systems, particularly CYP3A4, CYP2C9, and CYP2C19, through constitutive androstane receptor (CAR) nuclear receptor activation. This induction accelerates metabolism of co-administered drugs and can precipitate dangerous drug interactions when secobarbital is used with CNS depressants, anticoagulants, and oral contraceptives.
- CNS depressant combination risk: Alcohol, opioids, and benzodiazepines combined with secobarbital produce synergistic GABA-A depression that bypasses individual drug safety margins; this combination is responsible for the majority of fatal barbiturate overdoses
- Warfarin interaction: CYP2C9 induction accelerates warfarin metabolism, reducing anticoagulant efficacy; abrupt secobarbital discontinuation in patients on warfarin reverses this induction and can produce dangerous INR elevation
- Self-induction: Chronic secobarbital use induces its own metabolism, requiring escalating doses to maintain the same effect, a tolerance mechanism that narrows the therapeutic-to-lethal margin further over time
Secobarbital Uses and Indications
Secobarbital’s approved clinical indications have narrowed dramatically since the 1980s as benzodiazepines and non-benzodiazepine hypnotics (Z-drugs) replaced it for most applications. Current legitimate medical uses are limited to specific narrow contexts.
Historical vs. Current Medical Uses
- Historical use (1930s-1980s): Short-term insomnia, seizure control, procedural sedation, anesthesia premedication, tension and anxiety disorders
- Current FDA-approved use: Short-term treatment of insomnia (limited to 7 to 10 days), pre-operative sedation in anesthesia protocols where specifically indicated
- Medical aid in dying: Oral secobarbital 9 grams is the primary pharmacological protocol used in jurisdictions with legal medical aid in dying, producing loss of consciousness within 5 minutes and death within 1 to 2 hours
- Veterinary use: Pentobarb and secobarb compounds are used for animal euthanasia by licensed veterinarians
Secobarbital Addiction and Sedative-Hypnotic Use Disorder
Secobarbital produces physical and psychological dependence through neuroadaptive changes to GABA-A receptor density and sensitivity, with withdrawal that is clinically indistinguishable from severe alcohol withdrawal syndrome and carries the same seizure and delirium risk.
Signs and Symptoms of Secobarbital Addiction
The DSM-5-TR diagnostic criteria for sedative-hypnotic or anxiolytic use disorder apply to secobarbital dependence, with at least 2 of 11 criteria required for diagnosis over a 12-month period.
- Dose escalation beyond prescription: Taking secobarbital in larger amounts or over longer periods than originally prescribed, driven by tolerance-related dose escalation
- Withdrawal-driven use: Continued secobarbital use to avoid the anxiety, insomnia, tremors, and seizure risk that accompany abrupt discontinuation
- Compulsive procurement: Significant time spent obtaining, using, or recovering from secobarbital; includes doctor shopping for multiple prescriptions
- Continued use despite adverse consequences: Persistent use despite cognitive impairment, relationship problems, or occupational dysfunction caused by secobarbital’s CNS depressant effects
Secobarbital Withdrawal Syndrome
Secobarbital withdrawal is medically dangerous and can be life-threatening. Dr. Jerome Jaffe, who pioneered the first Comprehensive Drug Abuse Prevention and Control Act protocols, recognized barbiturate withdrawal as the most medically dangerous withdrawal syndrome encountered in addiction medicine, surpassing opioid withdrawal in seizure and mortality risk.
- Onset timeline: Withdrawal begins within 12 to 24 hours of last dose, with seizure risk highest in the first 24 to 72 hours
- Major withdrawal signs: Anxiety, tremors, diaphoresis, insomnia, nausea, tachycardia, hypertension, and hyperpyrexia progressing to grand mal seizures and delirium in severe cases
- Mortality without treatment: Untreated severe barbiturate withdrawal carries mortality rates of up to 5 percent from seizure-related complications
- Clinical management: The Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) protocol applies to barbiturate withdrawal management; phenobarbital taper or benzodiazepine substitution is the standard pharmacological approach
Sedative-Hypnotic Use Disorder Treatment at Riverside Recovery of Tampa
Secobarbital dependence and sedative-hypnotic use disorder require medically supervised detoxification under continuous clinical monitoring due to the seizure risk that accompanies abrupt discontinuation. At Riverside Recovery’s medical detox unit, barbiturate withdrawal is managed using CIWA-Ar scoring with phenobarbital or long-acting benzodiazepine substitution protocols.
Assistant Medical Director Erin Ikenberry, PA-C, notes: “Barbiturate withdrawal is the one withdrawal presentation that absolutely requires inpatient management. Unlike opioid withdrawal, which is rarely fatal, an undertreated barbiturate withdrawal can produce a seizure with no warning. Our CIWA-Ar monitoring is continuous, not scheduled, in the first 72 hours.”
Residential treatment following detox provides 30 to 90 days of structured care with dual diagnosis assessment for the anxiety and insomnia disorders that typically drive sedative-hypnotic use disorder. CBT-based sleep hygiene and anxiety management through evidence-based therapy addresses the root conditions that secobarbital was originally managing. Step-down through IOP and all programs are available with same-day assessment at (800) 871-5440.
Frequently Asked Questions
What is secobarbital used for?
Secobarbital’s current approved uses are limited to short-term insomnia treatment (7 to 10 days maximum) and pre-operative sedation. Its primary contemporary use is in medical aid in dying protocols in states with legal MAID laws, where a 9-gram oral dose produces rapid loss of consciousness and death. Its historical uses for anxiety, chronic insomnia, and seizure management were largely replaced by benzodiazepines in the 1980s.
Is secobarbital the same as Seconal?
Yes. Seconal is the brand name for secobarbital sodium manufactured by Eli Lilly. Generic secobarbital is chemically identical. Both refer to the same Schedule II barbiturate compound in 100mg capsule form. The Seconal brand is specifically associated with medical aid in dying protocols in states where it is legal.
Is secobarbital addictive?
Yes. Secobarbital produces rapid physical and psychological dependence through GABA-A receptor neuroadaptation. DSM-5-TR sedative-hypnotic use disorder criteria apply to secobarbital misuse. Regular users develop tolerance within weeks, requiring dose escalation to maintain the same effect, while abrupt discontinuation produces a dangerous withdrawal syndrome including seizure risk.
What happens if you take too much secobarbital?
Secobarbital overdose produces progressive CNS depression from sedation through stupor, coma, and fatal respiratory arrest. The therapeutic-to-lethal ratio is 3 to 5, meaning the lethal dose is only 3 to 5 times the therapeutic dose. Combined with alcohol or opioids, this ratio collapses further. Call 911 immediately for any suspected secobarbital overdose.
Can secobarbital withdrawal kill you?
Yes. Untreated barbiturate withdrawal can produce grand mal seizures and hyperpyrexia with mortality rates up to 5 percent without clinical management. Barbiturate withdrawal is medically more dangerous than opioid withdrawal and comparable in severity to severe alcohol withdrawal syndrome. Medical supervision with CIWA-Ar guided phenobarbital or benzodiazepine taper is required.
What is secobarbital’s street name?
Secobarbital street names include reds, red devils, red birds, sekkies, and F-40s, referring to the red capsule appearance of Seconal. These names originated in the 1960s and 1970s when barbiturate misuse was widespread. Today’s illicit secobarbital market is minimal compared to benzodiazepines and opioids, but diversion of medical-aid-in-dying supplies remains a documented concern.
References
- Jaffe, J. H. (1990). Drug addiction and drug abuse. In A. G. Gilman, T. W. Rall, A. S. Nies, & P. Taylor (Eds.), Goodman and Gilman’s The Pharmacological Basis of Therapeutics (8th ed., pp. 522–573). Pergamon Press.
- Drug Enforcement Administration. (2022). Barbiturates: Drug fact sheet. U.S. Department of Justice. Retrieved from dea.gov
- Substance Abuse and Mental Health Services Administration. (2023). National Survey on Drug Use and Health, 2022 results. U.S. Department of Health and Human Services.
- Sullivan, J. T., Sykora, K., Schneiderman, J., Naranjo, C. A., & Sellers, E. M. (1989). Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). British Journal of Addiction, 84(11), 1353–1357.
- U.S. Food and Drug Administration. (2022). Seconal Sodium (secobarbital sodium) capsules prescribing information. FDA.
- American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Publishing.
- Olsen, R. W., & Sieghart, W. (2009). GABA-A receptors: Subtypes provide diversity of function and pharmacology. Neuropharmacology, 56(1), 141–148.